Sign in or create an account to add this stock to your watchlist.
About Tandem Diabetes Care (NASDAQ:TNDM)
Tandem Diabetes Care, Inc. is a medical device company, which designs, develops and commercializes products for people with insulin dependent diabetes. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TNDM
CUSIPN/A
Phone858-366-6900
Debt
Debt-to-Equity Ratio6.45
Current Ratio2.62
Quick Ratio2.01
Price-To-Earnings
Trailing P/E Ratio-1.00
Forward P/E Ratio-8.85
P/E GrowthN/A
Sales & Book Value
Annual Sales$107.60 million
Price / Sales5.97
Cash FlowN/A
Price / CashN/A
Book Value$0.24 per share
Price / Book53.46
Profitability
EPS (Most Recent Fiscal Year)($12.87)
Net Income$-73,030,000.00
Net Margins-70.69%
Return on EquityN/A
Return on Assets-63.52%
Miscellaneous
Employees574
Outstanding Shares50,070,000
Tandem Diabetes Care (NASDAQ:TNDM) Frequently Asked Questions
What is Tandem Diabetes Care's stock symbol?
Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."
When did Tandem Diabetes Care's stock split? How did Tandem Diabetes Care's stock split work?
Shares of Tandem Diabetes Care reverse split before market open on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.
How were Tandem Diabetes Care's earnings last quarter?
Tandem Diabetes Care (NASDAQ:TNDM) posted its quarterly earnings results on Thursday, March, 1st. The medical device company reported ($1.23) EPS for the quarter, missing analysts' consensus estimates of ($1.11) by $0.13. The medical device company had revenue of $40 million for the quarter, compared to analyst estimates of $38.41 million. The company's revenue was up 61.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.48) earnings per share. View Tandem Diabetes Care's Earnings History.
When is Tandem Diabetes Care's next earnings date?
What price target have analysts set for TNDM?
7 brokers have issued 1-year price targets for Tandem Diabetes Care's shares. Their predictions range from $3.00 to $17.00. On average, they anticipate Tandem Diabetes Care's share price to reach $8.75 in the next twelve months. View Analyst Ratings for Tandem Diabetes Care.
Who are some of Tandem Diabetes Care's key competitors?
Some companies that are related to Tandem Diabetes Care include NuVasive (NUVA), Nevro (NVRO), iRhythm (IRTC), Mazor Robotics (MZOR), Luminex (LMNX), Glaukos (GKOS), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), Cardiovascular Systems (CSII), OraSure Technologies (OSUR), CryoLife (CRY), K2M Group (KTWO), Cerus (CERS) and AtriCure (ATRC).
Who are Tandem Diabetes Care's key executives?
Tandem Diabetes Care's management team includes the folowing people:
- Kim D. Blickenstaff, President, Chief Executive Officer & Director
- John F. Sheridan, Chief Operating Officer & Executive Vice President
- Leigh Vosseller, Chief Financial Officer & Senior Vice President
- David B. Berger, Secretary, Executive VP & General Counsel
- Brian B. Hansen, Chief Commercial Officer & Executive VP
Has Tandem Diabetes Care been receiving favorable news coverage?
Media headlines about TNDM stock have trended somewhat positive this week, Accern Sentiment reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Tandem Diabetes Care earned a daily sentiment score of 0.09 on Accern's scale. They also gave news stories about the medical device company an impact score of 45.88 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Tandem Diabetes Care's major shareholders?
Tandem Diabetes Care's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include First Light Asset Management LLC (9.46%), Frontier Capital Management Co. LLC (5.43%), Federated Investors Inc. PA (4.49%), Acuta Capital Partners LLC (2.69%), Wasatch Advisors Inc. (1.81%) and Millennium Management LLC (1.70%). Company insiders that own Tandem Diabetes Care stock include Christopher J Twomey, Dick Allen, John F Sheridan and Kim D Blickenstaff. View Institutional Ownership Trends for Tandem Diabetes Care.
Which institutional investors are buying Tandem Diabetes Care stock?
TNDM stock was bought by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, Federated Investors Inc. PA, Frontier Capital Management Co. LLC, Acuta Capital Partners LLC, Millennium Management LLC, venBio Select Advisor LLC, Wasatch Advisors Inc. and Millrace Asset Group Inc.. Company insiders that have bought Tandem Diabetes Care stock in the last two years include Christopher J Twomey, Dick Allen and Kim D Blickenstaff. View Insider Buying and Selling for Tandem Diabetes Care.
How do I buy shares of Tandem Diabetes Care?
Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tandem Diabetes Care's stock price today?
One share of TNDM stock can currently be purchased for approximately $12.83.
How big of a company is Tandem Diabetes Care?
Tandem Diabetes Care has a market capitalization of $642.37 million and generates $107.60 million in revenue each year. The medical device company earns $-73,030,000.00 in net income (profit) each year or ($12.87) on an earnings per share basis. Tandem Diabetes Care employs 574 workers across the globe.
How can I contact Tandem Diabetes Care?
Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at 858-366-6900 or via email at [email protected]
MarketBeat Community Rating for Tandem Diabetes Care (TNDM)
MarketBeat's community ratings are surveys of what our community members think about Tandem Diabetes Care and other stocks. Vote "Outperform" if you believe TNDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TNDM will underperform the S&P 500 over the long term. You may vote once every thirty days.
Tandem Diabetes Care (NASDAQ:TNDM) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Tandem Diabetes Care in the last 12 months. Their average twelve-month price target is $8.75, suggesting that the stock has a possible downside of 31.80%. The high price target for TNDM is $17.00 and the low price target for TNDM is $3.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Hold | Hold |
| Consensus Rating Score: | 2.86 | 2.63 | 2.33 | 2.33 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $8.75 | $9.6429 | $13.00 | $13.00 |
| Price Target Upside: | 31.80% downside | 74.69% upside | 343.69% upside | 343.69% upside |
Tandem Diabetes Care (NASDAQ:TNDM) Consensus Price Target History
Tandem Diabetes Care (NASDAQ:TNDM) Analyst Ratings History
Show:
(Data available from 5/20/2016 forward)
Tandem Diabetes Care (NASDAQ:TNDM) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Tandem Diabetes Care (NASDAQ TNDM) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.30%
Institutional Ownership Percentage: 14.75%
Tandem Diabetes Care (NASDAQ TNDM) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/6/2018 | Dick Allen | Director | Buy | 25,539 | $3.88 | $99,091.32 | |  |
| 2/9/2018 | Christopher J Twomey | Director | Buy | 75,000 | $2.00 | $150,000.00 | | |
| 2/9/2018 | Kim D Blickenstaff | CEO | Buy | 750,000 | $2.00 | $1,500,000.00 | | |
| 10/13/2017 | Kim D Blickenstaff | CEO | Buy | 285,700 | $3.50 | $999,950.00 | | |
| 3/23/2017 | Kim D Blickenstaff | CEO | Buy | 1,600,000 | $1.25 | $2,000,000.00 | 2,007,939 | |
| 8/1/2016 | John F Sheridan | EVP | Sell | 15,000 | $6.52 | $97,800.00 | 22,763 | |
| 5/2/2016 | John F Sheridan | COO | Sell | 2,000 | $10.61 | $21,220.00 | 7,295 | |
| 4/22/2016 | John F Sheridan | COO | Sell | 2,000 | $10.00 | $20,000.00 | 7,295 | |
| 3/7/2016 | John F Sheridan | COO | Sell | 4,000 | $10.01 | $40,040.00 | 9,295 | |
| 2/26/2016 | Dick Allen | Director | Buy | 10,000 | $8.24 | $82,400.00 | | |
| 12/1/2015 | John F. Sheridan | COO | Sell | 2,000 | $10.14 | $20,280.00 | 4,084 | |
| 11/2/2015 | John F. Sheridan | COO | Sell | 4,000 | $10.00 | $40,000.00 | 4,084 | |
| 9/14/2015 | John F. Sheridan | COO | Sell | 2,000 | $12.51 | $25,020.00 | 4,084 | |
| 5/1/2015 | John F Sheridan | COO | Sell | 2,000 | $13.72 | $27,440.00 | | |
| 4/1/2015 | John F Sheridan | COO | Sell | 2,000 | $12.47 | $24,940.00 | | |
| 2/2/2015 | John F Sheridan | COO | Sell | 2,000 | $12.06 | $24,120.00 | | |
| 1/2/2015 | John F Sheridan | COO | Sell | 2,000 | $12.75 | $25,500.00 | | |
| 12/12/2014 | Dick Allen | Director | Buy | 10,000 | $11.95 | $119,500.00 | | |
| 12/1/2014 | John F Sheridan | COO | Sell | 2,000 | $13.55 | $27,100.00 | | |
| 11/3/2014 | John F Sheridan | COO | Sell | 2,000 | $16.00 | $32,000.00 | | |
| 10/1/2014 | John F Sheridan | COO | Sell | 2,000 | $13.07 | $26,140.00 | | |
| 9/2/2014 | John F Sheridan | COO | Sell | 2,000 | $13.99 | $27,980.00 | | |
| 8/1/2014 | John F Sheridan | COO | Sell | 2,000 | $15.04 | $30,080.00 | | |
| 7/1/2014 | John F Sheridan | COO | Sell | 2,000 | $16.42 | $32,840.00 | | |
| 6/18/2014 | John F Sheridan | COO | Sell | 2,000 | $16.75 | $33,500.00 | | |
| 11/13/2013 | David B Berger | General Counsel | Buy | 2,000 | $15.00 | $30,000.00 | | |
| 11/13/2013 | Hlm Venture Partners Ii, L.P. | Major Shareholder | Buy | 200,000 | $15.00 | $3,000,000.00 | | |
(Data available from 1/1/2013 forward)
Tandem Diabetes Care (NASDAQ TNDM) News Headlines
| Source: |
|
Tandem Diabetes Care (NASDAQ:TNDM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Tandem Diabetes Care (NASDAQ:TNDM) Income Statement, Balance Sheet and Cash Flow Statement
Tandem Diabetes Care (NASDAQ TNDM) Stock Chart for Sunday, May, 20, 2018
Loading chart…
